You are successfully logged out.
Hematological malignancies are among the most common cancers in Europe. The great need for targeted and personalized therapy options is also reflected in the fundamental change in the field of hemato-oncology.
Yescarta is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Limitation of Use: Yescarta is not indicated for the treatment of patients with primary or secondary central nervous system lymphoma.
Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor unless ineligible to BTK inhibitor.
Limitation of use: Tecartus is not indicated for the treatment of patients with active central nervous system lymphoma.
Tecartus is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
For further information and full list of adverse events, please refer to the approved prescribing information as available at Israeli Ministry of Health website: https://israeldrugs.health.gov.il/#!/byDrug
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form at https://sideeffects.health.gov.il
Additionally, adverse events can be reported to Gilead: Report an Adverse Event